Here is my interpretation the COVID-19 trial announcement and comments from SI in the webcast, summarised in the form of a graph.
1 indicates the patient population when the trial was started
2 indicates the patient population when the trial was stopped
3 indicates the patient population Mesoblast and Novartis might seek to target after the trial data is unblinded
Keen to hear comments from others.
Ann: Mesoblast Update on COVID-19 ARDS Trial, page-744
-
- There are more pages in this discussion • 332 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.20 | $1.09 | $9.492M | 8.242M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 28 | 76946 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.20 | 91189 | 11 |
View Market Depth
| Last trade - 14.00pm 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |